In focus · trending topic

TNBC

2 stories · following the connections

Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC

Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC